| A living WHO guideline on drugs for covid-19 A Agarwal, BJ Hunt, M Stegemann, B Rochwerg, F Lamontagne, ... bmj 370, 2020 | 978* | 2020 |
| Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study S Rodríguez-Nóvoa, P Labarga, V Soriano, D Egan, M Albalater, ... Clinical Infectious Diseases 48 (11), e108-e116, 2009 | 304 | 2009 |
| Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy A Lister, T Nedjadi, NR Kitteringham, F Campbell, E Costello, B Lloyd, ... Molecular cancer 10, 1-13, 2011 | 282 | 2011 |
| Research capacity. Enabling the genomic revolution in Africa. C Rotimi, A Abayomi, A Abimiku, VM Adabayeri, C Adebamowo, ... Science (New York, NY) 344 (6190), 1346-1348, 2014 | 230 | 2014 |
| Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients C Wyen, H Hendra, M Vogel, C Hoffmann, H Knechten, NH Brockmeyer, ... Journal of antimicrobial chemotherapy 61 (4), 914-918, 2008 | 219* | 2008 |
| HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms RC Hartkoorn, W San Kwan, V Shallcross, A Chaikan, N Liptrott, D Egan, ... Pharmacogenetics and genomics 20 (2), 112-120, 2010 | 217 | 2010 |
| Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy T Doyle, C Smith, P Vitiello, V Cambiano, M Johnson, A Owen, AN Phillips, ... Clinical Infectious Diseases 54 (5), 724-732, 2012 | 192 | 2012 |
| Carbamazepine is not a substrate for P‐glycoprotein A Owen, M Pirmohamed, JN Tettey, P Morgan, D Chadwick, BK Park British journal of clinical pharmacology 51 (4), 345-349, 2001 | 192 | 2001 |
| FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 T Brevini, M Maes, GJ Webb, BV John, CD Fuchs, G Buescher, L Wang, ... Nature 615 (7950), 134-142, 2023 | 171 | 2023 |
| On the issue of transparency and reproducibility in nanomedicine HS Leong, KS Butler, CJ Brinker, M Azzawi, S Conlan, C Dufès, A Owen, ... Nature nanotechnology 14 (7), 629-635, 2019 | 171 | 2019 |
| The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ... Antimicrobial agents and chemotherapy 55 (9), 4122-4127, 2011 | 166 | 2011 |
| Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics U Arshad, H Pertinez, H Box, L Tatham, RKR Rajoli, P Curley, M Neary, ... Clinical Pharmacology & Therapeutics 108 (4), 775-790, 2020 | 157 | 2020 |
| Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein RC Hartkoorn, B Chandler, A Owen, SA Ward, SB Squire, DJ Back, ... Tuberculosis 87 (3), 248-255, 2007 | 156 | 2007 |
| Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine B Williamson, KE Dooley, Y Zhang, DJ Back, A Owen Antimicrobial agents and chemotherapy 57 (12), 6366-6369, 2013 | 149 | 2013 |
| Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy A Owen, S Rannard Advanced drug delivery reviews 103, 144-156, 2016 | 144 | 2016 |
| Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction SP Pushpakom, NJ Liptrott, S Rodríguez-Nóvoa, P Labarga, V Soriano, ... Journal of Infectious Diseases 204 (1), 145-153, 2011 | 144 | 2011 |
| Transport of gabapentin by LAT1 (SLC7A5) D Dickens, SD Webb, S Antonyuk, A Giannoudis, A Owen, S Rädisch, ... Biochemical pharmacology 85 (11), 1672-1683, 2013 | 142 | 2013 |
| A living WHO guideline on drugs to prevent covid-19 F Lamontagne, M Stegemann, A Agarwal, T Agoritsas, R Siemieniuk, ... bmj 372, 2021 | 136 | 2021 |
| Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study SH Khoo, R Fitzgerald, T Fletcher, S Ewings, T Jaki, R Lyon, N Downs, ... Journal of Antimicrobial Chemotherapy 76 (12), 3286-3295, 2021 | 131 | 2021 |
| Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human … O Janneh, E Jones, B Chandler, A Owen, SH Khoo Journal of antimicrobial chemotherapy 60 (5), 987-993, 2007 | 130 | 2007 |
Darren SmithProfessor of Bacteriophage Biology, Northumbria University在 northumbria.ac.uk 的电子邮件经过验证
Darren SmithProfessor of Bacteriophage Biology, Northumbria University在 northumbria.ac.uk 的电子邮件经过验证